Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System

NCT02359994 | Completed Results DMC

• 1 other identifier: PCT1101.011-C(02/15)
• Study Type: interventional
• Target: 324
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, multicenter, multidisciplinary, controlled clinical investigation evaluating the safety and efficacy of PerClot in achieving intraoperative hemostasis compared to a similar marketed hemostatic device. Three hundred and twenty four subjects across a maximum of 25 investigational sites undergoing open elective cardiac, general, or urological surgical procedures who meet the eligibility criteria will be intraoperatively randomized to receive no more than the entire contents of up to two 5 gram bellows of either the investigational device or a control hemostatic agent on a bleeding site, whose anatomic site is smaller than or equal to 25cm² and whose anatomic application site is smaller than or equal to 47cm², when bleeding is within the pre-defined bleeding severity range after any applicable conventional means for hemostasis are attempted as specified in the intraoperative procedures. Each investigational site is expected to enroll approximately 13-40 subjects. All investigational sites will be located in the U.S. Follow-up will occur at hospital discharge and 6 weeks post-device application. For oncologic subjects, an additional follow up will occur at 24 months post device application.

Conditions

Blood Loss, Surgical

Keywords

hemostasis

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Achievement of Hemostasis at 7 Minutes

  The primary objective of this clinical investigation is to demonstrate non-inferiority in the achievement of hemostasis of the treated bleeding site at 7 minutes in participants receiving PerClot compared to those receiving a control hemostatic device. The primary endpoint is the percentage of participants achieving hemostasis of the treated lesion at 7 minutes in each treatment group.

  7 minutes following application

Secondary Outcomes (1)

• Number of Participants With Achievement of Hemostasis at 5 Minutes

  5 minutes following application

Study Arms (3)

Cardiac Surgery

EXPERIMENTAL

For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps \> 2mm and large needle holes \> 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.

Device: PerClot Polysaccharide Hemostatic System; Device: Arista AH

General Surgery

EXPERIMENTAL

For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels \> 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria. For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels \> 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria.

Device: PerClot Polysaccharide Hemostatic System; Device: Arista AH

Urologic Surgery

EXPERIMENTAL

For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels \> 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release. For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels \> 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria.

Device: PerClot Polysaccharide Hemostatic System; Device: Arista AH

Interventions

PerClot Polysaccharide Hemostatic System DEVICE

During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.

Cardiac Surgery; General Surgery; Urologic Surgery

Arista AH DEVICE

During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.

Cardiac Surgery; General Surgery; Urologic Surgery

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is undergoing one of the following open elective cardiac, general, or urological surgical procedures: Cardiac procedure (Epicardium); Cardiac procedure (aortic anastomosis or aortotomy suture line); Liver resection; Total splenectomy; On-clamp partial nephrectomy; or Radical nephrectomy.
• Subject is willing and able to give prior written informed consent for investigation participation; and
• Subject is \> 22 years of age.
• Subject is undergoing one of the following elective procedures: Cardiac procedure (Epicardium); Cardiac procedure (Aortic Anastomosis or Aortotomy suture line); Liver resection; Total splenectomy; On-clamp partial nephrectomy; or Radical nephrectomy.
• Subject in whom all visible vessels or suture holes greater than or equal to 2mm in diameter have been ligated;
• Subject in whom there is bleeding at the specified area for each surgical procedure after any applicable conventional means for hemostasis are attempted as specified by the intraoperative protocol;
• Subject in whom the anatomic site is equal to or less than 25cm²;
• Subject in whom the anatomic application site is equal to or less than 47cm²; and
• Subject in whom the bleeding flux from the identified lesion is \> 0.000040\[g/(cm²•s)\] and ≤0.013\[g/(cm²•s)\].

You may not qualify if:

• Subject with known sensitivity to starch or starch-derived materials;
• Subject who has a clinically significant coagulation disorder or disease, defined as a platelet count \<100,000 per microliter, International Normalized Ratio \>1.5, or a PTT more than 1.5 times outside the laboratory's normal reference range;
• Subject who used corticosteroids (excluding inhalers, eye-drops, and dermatologic corticosteroids) within 6 weeks prior to surgery;
• Subject who has been treated with an investigational product and has not completed the entire follow-up period for that investigational product;
• Subject who is pregnant (as confirmed by pregnancy test), planning on becoming pregnant during the follow-up period, or actively breast-feeding; and
• Subject with poor blood glucose control as per glycosylated hemoglobin \> 9%.
• Subject undergoing a cardiac procedure in which there is no aortic anastomosis or aortotomy suture line to evaluate using the bleeding severity scale (i.e., not for treatment at the distal coronary artery bypass graft anastomosis);
• Subject in whom any major intraoperative bleeding incidences during the surgical procedure occurred (i.e., subject with assignment of an American College of Surgeons Advanced Trauma Life Support Hemorrhage Class of II, III, or IV Hemorrhage);
• Subject who has an active or potential infection at the surgical site, or whose surgical wound is defined as a wound classification of CO (Contaminated) or D (Dirty or Infected) based upon the Center for Disease Control and Prevention's wound classification system; and
• Subject who has undergone platelet receptor GP IIb/IIIa antagonist therapy less than 48 hours prior to surgery.

Sponsors & Collaborators

• Artivion Inc.: lead

Study Sites (1)

Indiana University d/b/a/ Methodist Research Institute

Indianapolis, Indiana, United States

Location

Related Publications (1)

• House MG, Kim R, Tseng EE, Kaufman RP Jr, Moon MR, Yopp A, Master VA. Evaluating the safety and efficacy of a novel polysaccharide hemostatic system during surgery: A multicenter multispecialty prospective randomized controlled trial. Surg Open Sci. 2024 May 3;19:205-211. doi: 10.1016/j.sopen.2024.04.009. eCollection 2024 Jun.

  PMID: 38800121 DERIVED

MeSH Terms

Conditions

Blood Loss, Surgical

Condition Hierarchy (Ancestors)

Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Intraoperative Complications

Results Point of Contact

• Title: Priya Patel
• Organization: Artivion

priya.patel@artivion.com

678-290-4358

Study Officials

• Michael House, MD

  Indiana University

  PRINCIPAL INVESTIGATOR

• Marc Moon, MD

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

• William Chapman, MD

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

• Ronald P Kaufman, MD

  Albany Medical College

  PRINCIPAL INVESTIGATOR

• Edward Chen, MD

  Emory University

  PRINCIPAL INVESTIGATOR

• Robin Kim, MD

  University of Utah

  PRINCIPAL INVESTIGATOR

• Derek DuBay, MD

  Medical University of South Carolina

  PRINCIPAL INVESTIGATOR

• Adam Yopp, MD

  University of Texas Southwestern Medical Center

  PRINCIPAL INVESTIGATOR

• Michael Argenziano, MD

  Columbia University

  PRINCIPAL INVESTIGATOR

• K. Scott Coffield, MD

  Baylor Scott and White Research Institute

  PRINCIPAL INVESTIGATOR

• Sean Castellucci, DO

  Manatee Medical Research Institute

  PRINCIPAL INVESTIGATOR

• Viraj Master, MD

  Emory University

  PRINCIPAL INVESTIGATOR

• Kiran Turaga, MD

  University of Chicago

  PRINCIPAL INVESTIGATOR

• Carlo B Ramirez, MD

  Thomas Jefferson University

  PRINCIPAL INVESTIGATOR

• Keith B Allen, MD

  St. Luke's Hospital

  PRINCIPAL INVESTIGATOR

• Elaine Tseng, MD

  San Francisco VA

  PRINCIPAL INVESTIGATOR

• Michael Jessen, MD

  University of Texas Southwestern Medical Center

  PRINCIPAL INVESTIGATOR

• Michael D'Angelica, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

• Jonathan Silberstein, MD, MPH

  Tulane University School of Medicine

  PRINCIPAL INVESTIGATOR

• S.Chris Malaisrie, MD

  Northwestern University

  PRINCIPAL INVESTIGATOR

• Charles St. Hill, MD

  University of Nevada, Las Vegas

  PRINCIPAL INVESTIGATOR

• Douglas Scherr, MD

  Weill Cornell Urology

  PRINCIPAL INVESTIGATOR

• Thomas Guzzo, MD

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

• Aaron Milbank, MD

  Minnesota Urology

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 3, 2015
• First Posted: February 10, 2015
• Study Start: April 1, 2015
• Primary Completion: January 11, 2019
• Study Completion: February 20, 2019
• Last Updated: March 17, 2022
• Results First Posted: March 17, 2022

Record last verified: 2022-03

Locations

US (1)